Articles
In-depth, research-backed writing on peptides. No hype, no filler — just what the evidence actually says.
Featured
Best Peptides for Recovery: Evidence-Aware Comparison
A cautious comparison of recovery-related peptides by evidence quality, uncertainty, and claim strength — not recommendations, protocols, or buying advice.
Peptides for Recovery: What the Evidence Actually Supports
A pillar guide to peptides for recovery that separates healing, soreness, and injury-repair claims while showing what the evidence actually supports.
All Articles
GLP-1 Drugs and Rare Optic-Nerve Risk: What the New NAION Studies Actually Show
Two large observational studies found a small association between GLP-1 receptor agonists and ischemic optic neuropathy, but the absolute event rate was very low and causation remains uncertain.
Setmelanotide and Hypothalamic Obesity: What the Phase 3 Trial Actually Shows
The phase 3 TRANSCEND trial found large BMI and hunger reductions with setmelanotide in acquired hypothalamic obesity, alongside a substantial adverse-event burden.
Afamelanotide and EPP: What Canada’s SCENESSE Approval Shows About Real Peptide Medicine
What afamelanotide SCENESSE does for adults with EPP, what the trials and labels show, and why regulated peptide medicine differs from tanning or research-peptide marketing.
Could Astronauts Make Peptide Medicines in Space? What the New Astropharmacy Study Actually Shows
A 2026 study ranked 26 peptide medicines for possible on-demand spaceflight production. Here is what the scoring shows—and what it does not prove.
AI Peptide Design: Why Binding Is Not the Same as Biological Effect
AI can predict that a peptide may bind a receptor, but binding alone does not reveal whether it activates, blocks, or meaningfully changes that receptor. TD3B shows why directionality matters—and why computational candidates still require laboratory and clinical validation.
Why Peptide Manufacturing Quality Is Hard: The EMA Synthetic-Peptide Guideline, Translated
A plain-English guide to synthetic peptide manufacturing quality, based on the EMA guideline effective June 1, 2026.
PepCan and HPV Peptide Vaccines: How to Read Early Cancer Vaccine Trials
The small PepCan trial did not prove that an HPV peptide vaccine prevents cancer recurrence. It shows why safety, immune signals, efficacy, statistical power, production problems, and conflicts must be read separately.
Peptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence
What the phase 3 COMPETE trial of [177Lu]Lu-edotreotide versus everolimus teaches about peptide receptor radionuclide therapy, disease-specific evidence, and why regulated peptide medicines should not be confused with wellness peptide marketing.
FDA Research Peptide Compounding Review: What It Is and What It Is Not
A cautious explainer on FDA's July 2026 review of seven peptide-related bulk drug substances for the 503A Bulks List, why staff opposition matters, and why the review is not FDA approval or proof of safety.
When a Peptide Enters Phase 1: What That Actually Means
Recent KIT2014 and Nubytide/8M2D peptide trial updates are useful examples of how to read early clinical-development news: meaningful, but not proof that a peptide works, is approved, or belongs in wellness marketing.
GLP-1 Side Effects: What Trials, Labels, and Online Communities Can Each Tell Us
GLP-1 side-effect claims mean different things depending on whether they come from clinical trials, FDA labels, adverse-event databases, or online communities. This evidence-method guide explains how to read each source without turning anecdotes into proof or labels into panic.
Research Use Only Peptides: What That Label Does and Does Not Mean
A cautious explainer on research use only peptides, what RUO labeling is meant to signal, and why it does not prove safety, legality, sterility, or suitability for human use.
Is Orforglipron a Peptide? The New Oral GLP-1 Pill Explained
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.
CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy
A cautious, evidence-aware explainer on CagriSema, the investigational semaglutide plus cagrilintide combination, and why the amylin + GLP-1 strategy is not just stronger semaglutide.
What Is Epitalon? Longevity Claims, Telomeres, and the Evidence Gap
Epitalon is searched as a telomere and longevity peptide, but the evidence is strongest for cell and animal biology and much weaker for proven human anti-aging outcomes.
What Is Tesamorelin? Visceral Fat Claims, Growth-Hormone Pathways, and Evidence
Evidence-aware explanation of tesamorelin, why it is searched around visceral fat and body composition, what the HIV-associated VAT evidence supports, how GH/IGF-1 pathway claims are often generalized, and where side-effect boundaries matter.
GLP-1 Peptides vs “Research Peptides”: What People Mean and Why It Matters
A clear, evidence-aware guide to why GLP-1 drugs are peptides, how semaglutide and tirzepatide differ from vague research-peptide marketing, and why regulatory status matters.
What Is MOTS-c? The Mitochondrial Peptide People Are Searching For
MOTS-c is a mitochondrial-derived peptide studied for metabolic and stress-response signaling, but longevity, fat-loss, and energy claims remain much less certain than the online hype suggests.
Sermorelin vs Ipamorelin: What’s the Difference?
Sermorelin and ipamorelin are both discussed as growth-hormone-secretagogue-related peptides, but they differ by pathway, evidence base, and safety uncertainty.
What Is CJC-1295? DAC vs No-DAC, Ipamorelin Combinations, and Evidence
Evidence-aware explanation of CJC-1295, DAC vs no-DAC terminology, why it is searched with ipamorelin, what human marker evidence can and cannot show, and where side-effect uncertainty remains.
Peptide Therapy Explained: What Clinics Mean, What’s Evidence-Based, and What’s Marketing
A cautious, evidence-aware guide to what peptide therapy means in clinics and marketing, how approved medicines differ from research compounds, and what questions to ask before trusting a claim.
BPC-157 and TB-500 Together: Evidence, Claims, and What’s Still Speculative
An evidence-aware guide to why BPC-157 and TB-500 are often discussed together, what mechanisms are claimed, what evidence exists separately versus as a combination, and where online recovery claims outrun the data.
What Is GHK-Cu? Copper Peptide Benefits, Skin Claims, Hair Growth, and Evidence
GHK-Cu is a copper-binding tripeptide with real skin and wound-biology research, plausible topical cosmetic relevance, weaker hair-growth certainty, and many consumer claims that run ahead of the evidence.
Peptide Side Effects: What's Known, What's Unknown, and What People Overstate
A cautious, evidence-aware guide to peptide side effects, long-term unknowns, online claims, and how to read safety discussions without mistaking anecdotes for proof.
How to Evaluate Peptide Claims Online
A practical framework for reading peptide claims online: how to separate human evidence from preclinical signals, spot hype, and avoid mistaking confident marketing for proof.
TB-500 Side Effects and Unknowns: What Safety Evidence Actually Shows
TB-500 is often discussed as a recovery peptide, but its human safety profile is still uncertain. Here is what is known, what is not known, and how to read side-effect claims carefully.
BPC-157 Side Effects and Unknowns: What Safety Evidence Actually Says
BPC-157 is often described as well tolerated, but human safety evidence is still thin. Here are the known side effects, theoretical risks, and biggest unknowns.
What Is BPC-157? Benefits, Evidence, Risks, and What We Actually Know
BPC-157 is a synthetic peptide often discussed for tissue repair, gut protection, and injury recovery, but most evidence is still preclinical.
What Is TB-500? An Evidence-Aware Overview
An evidence-aware overview of TB-500, its relationship to thymosin beta-4, what it is commonly discussed for, and where the evidence remains limited.
What Preclinical Actually Means in Peptide Research
A practical explainer on what preclinical actually means in peptide research, why it matters, and how to read early-stage evidence without inflating certainty.
BPC-157 vs TB-500: What's the Difference, and Which Recovery Peptide Question Are You Actually Asking?
BPC-157 and TB-500 are often discussed together for healing and recovery, but they have different mechanism stories, different common use cases, and similarly limited human evidence.
Peptide Research Status Explained: How to Judge the Evidence Before You Read Any Compound Page
Learn how to interpret peptide research stages so you can tell the difference between mechanistic theory, animal data, early human studies, and evidence that actually deserves confidence.